Status:
UNKNOWN
Cytomegalovirus (CMV) Perilymphatic Fluid
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Hearing Loss, Cochlear
Cytomegalovirus Congenital
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
In France, children cochlear implantation (CI) is performed 400 times per year. Causes of profound sensorineural hearing loss (SNHL) are represented by congenital malformation of the inner ear for 50 ...
Detailed Description
Data on etiology of hearing loss and CMV status are collected. Perilymphatic liquid is collected after cochleostomy using a 1ml seringue. The drop of liquid is deposited on a Guthrie card; on another ...
Eligibility Criteria
Inclusion
- Children (under 18-year-old) presenting with a Sensorineural Hearing Loss with an indication of cochlear implantation
Exclusion
- \-
Key Trial Info
Start Date :
December 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 10 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04724265
Start Date
December 10 2020
End Date
December 10 2022
Last Update
April 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert Debré Hospital
Paris, France, 75019